Speech-Language Pathologists in Bow, NH Accepting Medicare

9 Speech-Language Pathologists found. Showing 1 - 9

Mrs. Lynn A Van Cleave, CCC/SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 525 Clinton St, Bow, NH 03304 Phone: 603-226-3212

Mrs. Maureen W Heckman, MA, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 525 Clinton St, Bow, NH 03304 Phone: 603-225-4153    Fax: 603-226-3354

Mrs. Jean Marie Casey-spillane, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 17 Kelso Dr, Bow, NH 03304 Phone: 603-226-4401

Mary Babineau, MS,CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 525 Clinton St, Bow, NH 03304 Phone: 603-225-4153

Elizabeth Rutherford Duncan, M.S. Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 525 Clinton St, Bow, NH 03304 Phone: 603-225-4153

Mrs. Kristen Margaret Lanctot, MS Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 525 Clinton St, Bow, NH 03304 Phone: 603-225-4153    Fax: 603-226-3354

Babble And Beyond, Llc Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 9 Merrill Xing, Bow, NH 03304 Phone: 978-314-1493

Mrs. Amy T. Hooper Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 22 Bow Center Rd, Bow, NH 03304 Phone: 603-225-3049

Stacy Ann Kenney Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 22 Bow Center Rd, Bow, NH 03304 Phone: 603-225-3049

News Archive

Drug helps children with attention deficit/hyperactivity disorder (ADHD)

Children with attention deficit/hyperactivity disorder (ADHD) who take 36- or 54-mg doses of once-daily CONCERTA® (methylphenidate HCl) CII are more likely to achieve significantly greater symptom response and symptom reduction than children with ADHD who take CONCERTA 18 mg once daily or near-equivalent doses of methylphenidate three-times-a-day, a study shows.

New therapy shows promise in preventing brain damage after traumatic brain injury

Nearly three million people in the United States experience traumatic brain injury (TBI) every year, and there are no pre or post-TBI treatment options available. Now, a new novel therapy shows promise in preventing brain damage after traumatic brain injury.

Dissatisfaction with married life increases men's risk of death from stroke and premature mortality

Dissatisfaction with married life raises the risk of dying from a cerebrovascular accident: A new Tel Aviv University study reveals that perceiving marriage as unsuccessful is a significant predictor of death from a CVA and premature death among men, no less that well-known risk factors such as smoking and lack of physical activity.

ITelagen to host, support and manage EHR for Allergy and Asthma Associates

ITelagen, a leading provider of electronic health record (EHR) hosting and management announced that it was selected by Allergy and Asthma Associates of Northern California, San Jose, CA to host, support and manage EHR for their medical practice. The solution includes hosting of patient data in ITelagen's SAS-70 Type II certified datacenter and unlimited IT support for staff members.

King Pharmaceuticals commences Phase IIb clinical trial of ELADUR for chronic low back pain

DURECT Corporation announced today that its licensee, King Pharmaceuticals, has begun a Phase IIb clinical trial to evaluate ELADUR™ (TRANSDUR™-Bupivacaine) for the treatment of chronic low back pain. ELADUR is an investigational transdermal drug patch intended to deliver bupivacaine for up to 3 days from a single application.

Read more Medical News

› Verified 2 days ago